FindTrial
Sign In

Liver Biopsy using endoscopy

EUS Guided Liver Biopsy - Will it give better yield, more tissue with less complication?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022374
Enrollment
50
Registered
2019-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K701- Alcoholic hepatitis Health Condition 2: K730- Chronic persistent hepatitis, notelsewhere classified Health Condition 3: K768- Other specified diseases of liver Health Condition 4: K758- Other specified inflammatory liverdiseases

Interventions

Intervention1: Endoscopic USG guided Liver biopsy patients recruited a a part of this trial: Liver biopsy would be done by Endoscopic Ultrasound using Acquire needle Control Intervention1: Percutaneou

Sponsors

Asian Institute of Gastroenterology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any undiagnosed hepatic disease (after extensive investigation - serological as well as imaging) requiring a liver biopsy. 2. Patients of NAFLD who need LBx. 3. Alcoholic hepatitis patients needing biopsy. 4. Any patient with unexplained transaminesemia > 1.5 times ULN needing a liver biopsy as advised by Hepatologist.

Exclusion criteria

Exclusion criteria: 1. Any liver Space occupying lesion suspicious of malignancy 2. Platelet count 3. INR > 1.5 4. Pregnancy 5. Severe cardiovascular and pulmonary diseases. 6. Recent use of antiplatelet agents within 5 days of the procedure. 7. Unwilling to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Diagnostic yield with EUS guided liver biopsy â?? Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed. The biopsy specimens would be reported independently by two pathologists who would be masked to the source of tissue (right/ left lobe).Timepoint: 1 month—

Secondary

MeasureTime frame
1. Safety of procedure 2. Duration of procedure 3. Cost of the procedure 4. Size of tissue acquired 5. Number of portal tracts 6. Risk of complications 7. Difference in NAS score between right lobe and right vs left lobe 8. Comparison with historical cohort of Per cutaneous LBx 9. Patient recovery time when compared to per cutaneous liver biopsy procedure.Timepoint: 1 month—

Countries

India

Contacts

Public ContactMithun Sharma

Asian Institute of Gastroenterology

drmithunsharma@gmail.com08790622655

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026